🇺🇸 FDA

Drug profile · INN

ixazomib citrate

NINLARO

approved
US status
approved
Patents linked
2
News articles
0

Quick answer

ixazomib citrate (NINLARO) is an FDA-listed pharmaceutical active ingredient. Associated with Takeda Pharmaceuticals International AG. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN ixazomib citrate
Brand NINLARO
Route ORAL
Formulation CAPSULE
Originator Takeda Pharmaceuticals International AG

Related patents

Search patents →

  1. US 11053261

    Solid state forms of ixazomib citrate

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10604537

    Solid state forms of ixazomib citrate

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is ixazomib citrate?

ixazomib citrate (NINLARO) is an FDA-listed pharmaceutical active ingredient. Associated with Takeda Pharmaceuticals International AG. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for ixazomib citrate?

NINLARO is a marketed brand name for ixazomib citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of ixazomib citrate?

ixazomib citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.